Physician profile
Kenneth Wiseman
NPI 1427083849
$7,860.39
in general payments reported to CMS, 2019-2025
36 companies · $677 in 2025
The $677 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,838 · 2020: $508 · 2021: $1,719 · 2022: $1,606 · 2023: $922 · 2024: $592 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,190.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,309.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $969.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $685.42 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $490.96 | 2019-2025 | Ubrelvy, Vraylar |
| Sanofi-Aventis U.S. LLC | $479.88 | 2019-2022 | |
| Lilly USA, LLC | $459.12 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astellas Pharma US INC | $434.78 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $342.03 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $340.87 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.57 | 2019-2023 | Trulance, Xifaxan |
| Pfizer INC. | $226.90 | 2019-2024 | |
| Daiichi Sankyo INC. | $219.22 | 2021-2022 | |
| Exact Sciences Corporation | $211.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $207.39 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $176.64 | 2021-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $151.56 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $134.67 | 2021-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.03 | 2019-2025 | Jardiance |
| Abbott Laboratories | $80.89 | 2022 | |
| Amarin Pharma, INC. | $70.95 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $61.38 | 2019-2020 | |
| Allergan, INC. | $55.40 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $55.01 | 2023-2024 | Ingrezza |
| Amgen INC. | $52.65 | 2023-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $46.77 | 2021-2024 | Abilify Asimtufii, Abilify Maintena |
| Mannkind Corporation | $33.43 | 2019-2021 | |
| Dexcom, INC. | $29.72 | 2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $27.69 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $24.54 | 2021 | |
| Inspire Medical Systems, INC. | $20.85 | 2025 | Inspire |
| Hologic Sales and Service, LLC | $19.35 | 2024 | Aptima |
| Sumitomo Pharma America, INC. | $17.91 | 2024 | Gemtesa |
| Phadia US INC. | $14.70 | 2019 | |
| Shield Therapeutics INC | $13.95 | 2023 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $12.47 | 2019 | |
| Corcept Therapeutics | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Wiseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.